Chicago Partners Investment Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Chicago Partners Investment Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-174	Closed	-$1K	–	1066
2018 Q3	$1K	Hold	174	–	–	﹤0.01%	1055
2018 Q2	$1K	Hold	174	–	–	﹤0.01%	947
2018 Q1	$1K	Hold	174	–	–	﹤0.01%	915
2017 Q4	$1K	Hold	174	–	–	﹤0.01%	866
2017 Q3	$1K	Buy	+174	New	+$1.47K	﹤0.01%	946
2017 Q2	–	Sell	-174	Closed	-$2K	–	842
2017 Q1	$2K	Hold	174	–	–	﹤0.01%	529
2016 Q4	$2K	Hold	174	–	–	﹤0.01%	515
2016 Q3	$3K	Hold	174	–	–	﹤0.01%	476
2016 Q2	$2K	Hold	174	–	–	﹤0.01%	430
2016 Q1	$3K	Hold	174	–	–	﹤0.01%	414
2015 Q4	$5K	Hold	174	–	–	﹤0.01%	449
2015 Q3	$8K	Hold	174	–	–	﹤0.01%	358
2015 Q2	$6K	Buy	174 +28	+19%	+$814	﹤0.01%	390
2015 Q1	$6K	Sell	146 -28	-16%	-$948	﹤0.01%	417
2014 Q4	$7K	Buy	+174	New	+$4.79K	﹤0.01%	416

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Chicago Partners Investment Group's NAVB Position: Q4 2018 in Review

Chicago Partners Investment Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2018, closing a stake of 174 shares — an estimated $1K sold.

Chicago Partners Investment Group first reported a position in NAVB in Q4 2014 and held it in 15 quarters. The position peaked at $8K in Q3 2015. 56 funds tracked by Wall St. Rank hold NAVB as of Q4 2018.

Chicago Partners Investment Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2018 after selling out during the quarter.
Chicago Partners Investment Group sold 174 Navidea Biopharmaceuticals Inc. shares in Q4 2018, an estimated $1K.
Chicago Partners Investment Group first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 15 quarters.
Chicago Partners Investment Group's Navidea Biopharmaceuticals Inc. position peaked at $8K in Q3 2015.
56 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2018.

Based on Chicago Partners Investment Group's 13F filing for Q4 2018, filed 11 Jan 2019.